Thomas Reiser: Final Day as Executive Director – Closing a Remarkable Chapter at ISTH
Thomas Reiser, Executive Director at the International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Today is my final day as Executive Director at the International Society on Thrombosis and Haemostasis (ISTH).
I close this remarkable 14+ year chapter with immense gratitude for the trust placed in me, for the privilege of serving a mission and organization I believe so deeply in, and for the many extraordinary people who made this journey meaningful every step of the way.
To the ISTH team, Council, volunteers, members, partners, and the hashtag#thrombosis and hashtag#hemostasis community around the world: Thank you for allowing me to be part of this amazing community, the collaboration, dedication, and the friendships that will stay with me long after today.
I leave with great pride for all we have been able to accomplish together.
At the same time, I look forward to continuing to create impact, wherever the next chapter may lead me.
With heartfelt thanks and deep appreciation.”
Find more posts featuring Thomas Reiser on Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning